Lilly's GLP-1 Cash Funds Pain Play; Broadcom Insider Buys

Eli Lilly (LLY) bought 4E Therapeutics, a private biotech developing oral pain drugs, for an undisclosed sum Tuesday. 4E's lead compound targets MNK inhibitors, a mechanism first studied in cancer that is now being applied to chronic pain. Phase 1 data showed a clean safety profile, the company said.

The deal is small. It follows Lilly's May agreement to buy SiteOne Therapeutics for $1 billion. SiteOne's drug is in the same class as Vertex's Journavx. The pain market is a large opportunity as doctors seek non-opioid alternatives. It is also a difficult therapeutic area. Lilly removed a pain drug from its pipeline last year, Biopharma Dive reported.

For investors, the Lilly narrative remains tied to GLP-1 revenue. Obesity and diabetes treatments will continue to drive the vast majority of revenue, the company has said. The cash from those drugs gives Lilly the ability to make many small bets on early-stage science. The 4E acquisition is one such bet. A lot has to go right before the compound reaches late-stage trials.

The broader market was mixed Tuesday. The S&P 500 eased after a strong Monday rally. Technology lagged, giving back some of the prior day's 3% Nasdaq gain. SpaceX's post-IPO rally continued, briefly surpassing Amazon and Microsoft in market capitalization. Microsoft (MSFT) ended the session down 1.7% at $393.12. Its Alpha Score is 56, a moderate reading.

The rotation into cyclicals continued. Financials and industrials led the day's gains. Utilities also advanced. The move comes as tech's concentration risk remains a concern, with a handful of large-cap names accounting for a disproportionate share of market gains. Oil fell again, with WTI crude dropping below $76 a barrel, its lowest since the Middle East conflict began. Lower oil and rates help the Fed justify holding rates steady.

Broadcom (AVGO) also saw a signal. Shares are down $100 from their June 2 high after the company's post-earnings guidance disappointed. On Thursday, board chairman Harry You bought 1,000 shares at $373.57, a securities filing showed Monday. The purchase is small, about $374,000. It is a start.

Broadcom has a history of stepping in after selloffs. In April 2025, CEO Hock Tan authorized a $10 billion buyback five days after President Trump announced Liberation Day tariffs. The stock doubled from that point. The buyback authorization remains available. The insider buy is the first such purchase since the sell-off.

Wednesday brings retail sales data at 8:30 a.m. ET, followed by the Fed's June meeting decision at 2 p.m. Markets expect the Fed to hold rates unchanged. The oil decline has made it easier for the Fed to justify keeping rates steady the rest of the year, the Homestretch report noted. Tech's concentration risk remains a theme as capital rotates into cyclicals.